Navigation Links
Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
Date:1/31/2013

SAN FRANCISCO, Jan. 31, 2013 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced the expansion of its senior management team with the appointment of Edward C. Albini as chief financial officer. Mr. Albini has more than 25 years of life science industry experience, including more than 14 years in various financial management positions at Genentech.

"Ed joins Sutro at a very exciting time as we continue to advance our own pipeline and to collaborate with pharmaceutical and biotech companies utilizing our novel, cell-free approach for the design, development and manufacturing of next-generation antibody drug conjugates (ADCs) and bispecific antibodies," said William Newell , chief executive officer of Sutro Biopharma. "He brings a tremendous skill set and depth of experience that will provide us with important insight and direction at this important stage for our company."

Mr. Albini joins Sutro from Itero Biopharmaceuticals, a company focusing on the development and commercialization of protein therapeutics, where he was chief financial officer. Prior to joining Itero, he was chief financial officer at Novacea, where he was responsible for oversight and management of all financial activities, including debt and equity financings, strategic financial evaluation, financial planning and investor relations. Earlier, Mr. Albini was the chief financial officer of Lynx Therapeutics, where he led equity and debt offerings and negotiated revenue-bearing agreements for the company. He worked for more than 14 years in various financial management positions at Genentech, including director of finance for international operations and director of financial planning and analysis. Mr. Albini holds a master's in business administration from the University of California, Berkeley, and a bachelor's degree in accounting from Santa Clara University. He is a certified public accountant.

About Sutro Biopharma

Sutro Biopharma, located in South San Francisco, has developed a cell-free biochemical protein synthesis platform that enables the rapid design, engineering, testing and scalable production of novel proteins, including those containing site-specific modifications and non-natural amino acids. Sutro's platform allows the rapid and systematic exploration of many protein variants to identify drug and vaccine candidates. Once product candidates are identified, production can be rapidly and predictably scaled up to commercial levels. Sutro has established a Good Manufacturing Practice (cGMP) facility for the production of clinical supplies of materials using its biochemical protein synthesis platform.  Using this platform, Sutro is collaborating with pharmaceutical and biotech companies, including Celgene, Pfizer and Sanofi Pasteur, to discover and develop novel vaccines, peptide-based therapeutics, antibody drug conjugates and bifunctional antibodies to meet unmet medical needs. These products will significantly extend the clinical impact of current approaches and are beyond what can be envisioned with current cell-based expression technologies. For more information, visit www.sutrobio.com.

Media Contacts:

David Schull or Martina Schwarzkopf , Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4292
(347) 591-8785 (mobile)
david.schull@russopartnersllc.com  
martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Sutro Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sutro Announces Newly Formed Scientific Advisory Board
2. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
3. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
4. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
5. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
9. John A. Orwin Joins Array BioPharma Board Of Directors
10. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... 2017  Kibow Biotech Inc., a pioneer in developing ... of a new patent covering a unique method for ... Patent and Trademark Office on May 23 rd ... of Bio award in 2014 in San ... approaches to chronic disease. Renadyl™, the first and only ...
(Date:6/19/2017)... ... 2017 , ... As Vice President, Product Services, Mr. Guinter ... support, and client process and SOP development. , Mr. Guinter brings a wealth ... for service providers and top-tier pharmaceuticals, and as an independent consultant supported a ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... has just announced two more sessions of its “From the Helm” Webinar Series. ... the world of online templates for design control exercises. Led by David Cronin, ...
(Date:6/15/2017)... CT (PRWEB) , ... June 15, 2017 , ... ... that it has secured a Series B round of financing in the amount ... a group of private investors participated in the round. , The Series B ...
Breaking Biology Technology:
(Date:6/14/2017)... -- IBM (NYSE: IBM ) is introducing several innovative partner ... developing collaboration between startups and global businesses, taking place in ... event, nine startups will showcase the solutions they have built ... France is one of ... 30 percent increase in the number of startups created between ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
Breaking Biology News(10 mins):